IgM paraproteinaemic neuropathies
- 1 October 2004
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Neurology
- Vol. 17 (5), 599-605
- https://doi.org/10.1097/00019052-200410000-00010
Abstract
To conduct a critical review of recent studies on the pathogenesis and treatment of IgM paraproteinaemic neuropathies and analyse their implication for patient management.A better definition and classification of IgM monoclonal gammopathies has led to recommendations on therapeutic strategies for these patients, particularly for those with the asymptomatic form of Waldenström macroglobulinemia. Studies on the pathogenetic role of IgM paraprotein in neuropathy have led to the identification of a novel antibody reactivity against trisulfated heparin disaccharide, which was associated with painful, predominantly sensory, axonal distal neuropathy. Pathological studies on patients with axonal polyneuropathy and no antibody reactivity of the IgM paraprotein have shown that vasculitis may play an important role in this form of neuropathy, as possibly confirmed by its positive response to steroids. A number of open pilot trials have addressed the effect in IgM paraproteinaemic neuropathies of the humanized monoclonal antibody (rituximab) directed against the CD20 antigen. Even if the results of these studies are less promising than initially hoped, they provide evidence that rituximab may be effective in some patients with this neuropathy.New insights into the pathogenesis of axonal forms of IgM paraproteinaemic neuropathy have derived from the identification of novel antibody reactivity and of vasculitis. The latter finding may justify the use of steroids, otherwise ineffective in IgM paraproteinaemic neuropathy. Rituximab has opened the way to more selective and apparently safer immune therapies for this neuropathy, but its efficacy needs to be confirmed by randomized controlled trials.Keywords
This publication has 42 references indexed in Scilit:
- Waldenström macroglobulinaemiaThe Lancet Oncology, 2003
- Monoclonal gammopathies of undetermined significance: a reviewImmunological Reviews, 2003
- Malignant transformation in IgM monoclonal gammopathy of undetermined significanceSeminars in Oncology, 2003
- Long-term follow-up of IgM monoclonal gammopathy of undetermined significanceSeminars in Oncology, 2003
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- POEMS syndrome: definitions and long-term outcomeBlood, 2003
- Sensory neuropathy with monoclonal IgM binding to a trisulfated heparin disaccharideMuscle & Nerve, 2002
- MONOCLONAL GAMMOPATHIES OF UNDETERMINED SIGNIFICANCEReviews in Clinical and Experimental Hematology, 2002
- Neuropathies Associated with ParaproteinemiaThe New England Journal of Medicine, 1998
- Frequency and clinical correlates of anti–neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathyAnnals of Neurology, 1994